LGND Ligand Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: LGND

Price (delayed)

$60.9

Market cap

$1.06B

P/E Ratio

38.79

Dividend/share

N/A

EPS

$1.57

Enterprise value

$1.04B

Ligand Pharmaceuticals is a biopharmaceutical company located in San Diego, California. Founded in 1987 as Progenx Inc., the company went public in 1992.

Highlights
Ligand Pharmaceuticals's quick ratio has surged by 167% QoQ
The debt has plunged by 92% YoY and by 87% from the previous quarter
The equity has declined by 17% year-on-year but it has grown by 2.9% since the previous quarter
Ligand Pharmaceuticals's gross margin has decreased by 4.7% YoY but it has increased by 3.5% QoQ
The gross profit has declined by 17% year-on-year and by 10% since the previous quarter
The revenue has declined by 13% year-on-year and by 13% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ligand.com
Peers: AMGN MRK PFE LLY

Key stats

What are the main financial stats of LGND
Market
Shares outstanding
17.36M
Market cap
$1.06B
Enterprise value
$1.04B
Valuations
Price to earnings (P/E)
38.79
Price to book (P/B)
1.58
Price to sales (P/S)
6.44
EV/EBIT
11.99
EV/EBITDA
7.79
EV/Sales
6.36
Earnings
Revenue
$163.48M
EBIT
$86.78M
EBITDA
$133.59M
Free cash flow
$99.06M
Per share
EPS
$1.57
Free cash flow per share
$5.73
Book value per share
$38.49
Revenue per share
$9.46
TBVPS
$18.31
Balance sheet
Total assets
$758.11M
Total liabilities
$93.21M
Debt
$11.67M
Equity
$664.89M
Working capital
$247.32M
Liquidity
Debt to equity
0.02
Current ratio
9.42
Quick ratio
8.41
Net debt/EBITDA
-0.13
Margins
EBITDA margin
81.7%
Gross margin
74.8%
Net margin
16.6%
Operating margin
15.3%
Efficiency
Return on assets
3.2%
Return on equity
4%
Return on invested capital
31.6%
Return on capital employed
11.9%
Return on sales
53.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LGND stock price

How has the Ligand Pharmaceuticals stock price performed over time
Intraday
3.47%
1 week
-3.79%
1 month
-6.87%
1 year
-21.04%
YTD
-8.83%
QTD
-15.53%

Financial performance

How have Ligand Pharmaceuticals's revenue and profit performed over time
Revenue
$163.48M
Gross profit
$122.33M
Operating income
$25.03M
Net income
$27.16M
Gross margin
74.8%
Net margin
16.6%
The company's operating income has shrunk by 61% YoY and by 30% QoQ
Ligand Pharmaceuticals's operating margin has shrunk by 55% YoY and by 20% QoQ
The net margin has grown by 30% from the previous quarter
The gross profit has declined by 17% year-on-year and by 10% since the previous quarter

Growth

What is Ligand Pharmaceuticals's growth rate over time

Valuation

What is Ligand Pharmaceuticals stock price valuation
LGND P/E details
P/E
38.79
P/B
1.58
P/S
6.44
EV/EBIT
11.99
EV/EBITDA
7.79
EV/Sales
6.36
Ligand Pharmaceuticals's EPS has increased by 13% QoQ
LGND's P/B is 45% lower than its 5-year quarterly average of 2.8 and 19% lower than its last 4 quarters average of 1.9
The equity has declined by 17% year-on-year but it has grown by 2.9% since the previous quarter
The price to sales (P/S) is 43% lower than the 5-year quarterly average of 11.0 and 10% lower than the last 4 quarters average of 6.9
The revenue has declined by 13% year-on-year and by 13% since the previous quarter

Efficiency

How efficient is Ligand Pharmaceuticals business performance
Ligand Pharmaceuticals's return on sales has increased by 26% QoQ
The ROA has increased by 23% QoQ
The company's return on equity rose by 21% QoQ
Ligand Pharmaceuticals's ROIC has increased by 16% from the previous quarter

Dividends

What is LGND's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LGND.

Financial health

How did Ligand Pharmaceuticals financials performed over time
LGND's current ratio has soared by 184% since the previous quarter
Ligand Pharmaceuticals's quick ratio has surged by 167% QoQ
The debt is 98% less than the equity
The debt has plunged by 92% YoY and by 87% from the previous quarter
The debt to equity has plunged by 89% YoY and by 86% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.